From: CYP1A2polymorphism −1545C > T (rs2470890) is associated with increased side effects to clozapine
Patients | TT (n=54) | TC/CC (n=133) | PP between groups |
---|---|---|---|
Males | 32 (59.3%) | 78 (58.6%) | NS |
Regular smokers | 29 (52.7%) | 65 (49.6%) | NS |
Antipsychotic co-medication | 18 (33.3%) | 48 (36.1%) | NS |
Atypical | 14 (25.9%) | 31 (23.3%) | |
Conventional | 2 (3.7%) | 16 (12.0%) | |
Both | 2 (3.7%) | 1 (0.8%) | |
Mood stabilizer adjuvant therapy | 24 (44.4%) | 31 (23.3%) | 0.004 |
SSRI/SNRI adjuvant therapy | 21 (38.9%) | 46 (34.6%) | NS |
Clozapine + norclozapine serum level mol/l (mean+SD) | 2.21+0.98 | 2.45+1.36 | 0.20 |
Clozapine/norclozapine ratio (mean+SD) | 1.68+0.60 | 1.71+0.59 | 0.78 |
Clozapine dose/serum level ratio (mean+SD) | 441+195 | 405+309 | 0.44 |
Clozapine dose mg (mean+SD) | 431+132 | 390+150 | 0.078 |
Antipsychotic total dose mg* (mean+SD) | 971+380 | 883+389 | 0.17 |